BURLINGAME, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) — Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Five Prime Therapeutics, Inc. (NASDAQ:FPRX). The non-exclusive license grants Five Prime rights to use the AlivaMab Mouse for antibody drug discovery and development. “Ablexis is … Continued
Ablexis Announces Availability of the AlivaMab Mouse Technology and Settlement of the Litigation with Regeneron Pharmaceuticals, Inc.
Novel, Fully Validated Transgenic Mouse Platform for the Discovery of Antibody Therapeutics Delivered to Pfizer and Other Licensees Earlier in 2014 San Francisco – December 4, 2014 – Ablexis, LLC today announced the completion and delivery to its licensees of its AlivaMab Mouse technology, an innovative and unique platform for discovery of the next generation of breakthrough … Continued